Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,262.56 89.32 0.55%
S&P 500 1,842.98 12.37 0.68%
NASDAQ 4,034.16 11.47 0.29%
Ticker Volume Price Price Delta
STOXX 50 3,091.52 -40.05 -1.28%
FTSE 100 6,541.61 -42.15 -0.64%
DAX 9,173.71 -165.46 -1.77%
Ticker Volume Price Price Delta
NIKKEI 14,385.53 388.72 2.78%
TOPIX 1,163.96 27.87 2.45%
HANG SENG 22,817.64 146.38 0.65%

Apricus Biosciences Announces Corporate Update Conference Call



Apricus Biosciences Announces Corporate Update Conference Call

Conference Call/Webcast to be Held Monday, August 12, 2013 at 9:00 AM ET

SAN DIEGO, Aug. 9, 2013 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc.
("Apricus Bio" or the "Company") (Nasdaq:APRI) (www.apricusbio.com) announced
today that it will hold a conference call to discuss its recent corporate
highlights on Monday, August 12, 2013 at 9:00 AM ET. 

The call can be accessed in the U.S. by dialing (877) 407-8031 and outside of
the U.S. by dialing (201) 689-8031 and asking the conference operator for the
Apricus Bio Conference Call. The conference call will also be webcast live at
http://www.investorcalendar.com/IC/CEPage.asp?ID=171412. The teleconference
replay will be available for one week by dialing in the U.S. (877) 660-6853
and outside of the U.S. by dialing (201) 612-7415. Replay Passcode 418593 is
required for playback. The webcast replay will be available for three months.

About Apricus Biosciences, Inc.

Apricus Biosciences, Inc. (APRI) is a pharmaceutical company that develops and
markets innovative treatments that help large patient populations across
numerous, large-market therapeutic classes including male and female sexual
health. The Company has one approved product, Vitaros^®, for the treatment of
erectile dysfunction, which is now approved in Europe and Canada and will be
commercialized by Apricus Bio's marketing partners which include, Abbott
Canada, Takeda Pharmaceuticals International GmbH, Sandoz, and Bracco SpA.
Femprox^®, the Company's product candidate for the treatment of female sexual
interest / arousal disorder, has successfully completed a nearly 400-subject
proof-of-concept study.

For further information on Apricus Bio, visit http://www.apricusbio.com.

CONTACT: Apricus Bio Investor Relations:
         David Pitts or Lourdes Catala
         Argot Partners
         212-600-1902
         david@argotpartners.com
         lourdes@argotpartners.com

Apricus logo
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement